{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Expert Perspectives and Practical Guidance on IO Combination Strategies for Advanced Renal Cell Carcinoma

Activity Steps

1 Take Pre-test
2 Activity
3 Take Post-test 4Certificate

Description

OlogyImage

To access this FREE activity, please login (or register first in a new tab). After login, click on the blue +Cart button and enter the Coupon Code: RCCFREE

Do you find it difficult to keep up to date with clinical trial outcomes of new therapies for advanced renal cell carcinoma? Many physicians find the dynamic field of treatment strategies for advanced RCC daunting, and share a lack of understanding of novel treatments and of how to select patients appropriately. This 1-hour learning activity, containing a 30-minute webcast and two interactive patient cases, is developed to improve your knowledge of the latest immunotherapy (IO) combination strategies regarding the characterization and treatment of advanced RCC. Two leading experts in the field of RCC, Dr David McDermott and Dr Lauren Harshman, discuss the latest data on relevant IO combination strategies, including novel IO/anti-VEGF combinations, and elucidate challenges that still lie ahead. In addition, they offer practical guidance on how to relate this new clinical trial data to your own clinical practice.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, and other HCPs involved in the diagnosis and treatment of patients with RCC.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Discuss the rationale and clinical evidence for IO combination regimens in the treatment of advanced RCC, including immunotherapy with VEGFR TKIs
  2. Evaluate recent clinical trial data assessing IO combination regimens
  3. Explain the impact of emerging IO/anti-angiogenic combination strategies on the care of patients with advanced RCC
  4. Identify effective strategies for the early detection and management of adverse events related to IO and IO combination regimens
  5. Develop a treatment plan that integrates the use of optimal IO drug combinations in patients with advanced RCC by applying the latest evidence to improve patient outcomes

Disclosures

Dr. McDermott has disclosed that he was/is a consultant/advisor BMS, Pfizer, Merck, Novartis, Exelixis, Array BioPharma, Genentech BioOncology, Alkermes, Jounce Therapeutics, X4 Pharma, Peloton Therapeutics, EMD Serono, and Eli Lilly; was/is a recipient grant/research funds from

Dr. Harshman has disclosed that she was/is a consultant/advisor for Bayer, Merck, Dendreon/Valient, Genentech BioOncology, Pfizer, Exelixis, Kew Group, Covus, Novartis, Jounce Therapeutics, OncLive, and PER; was/is a recipient of grant/research funds from Bayer, Sotio, BMS, Merck, Takeda, Dendreon/Valient, Janssen, Medivation/Astellas, Genentech BioOncology, and Pfizer.

Non-Faculty All planners in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interest in, any commercial organizations pertaining to this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Lippincott CME Institute and Ology Medical Education do not recommend the use of any agent outside of the labeled indications.

Financial Support

This activity has been supported by an independent educational grant from EMD Serono, Pfizer, and MSD.

Method of Participation

1. Site registration is required to begin this activity. Please click the blue "+Planner" button and follow the instructions to register.

2. Read the educational objectives, accreditation information, and faculty disclosures.

3. Take the pre-test.

4. Watch the webcast.

5. Take the post-test and complete the evaluation.

Price: $100.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planner
Professions: Physician
Test Code: WEB82019
Published: August 2019
Expires: 1/1/2026
Sources: Grant Supported
Required Passing Score: 4/5 (80%)
Authors: David F. McDermott, MD. Professor of Medicine, Dana-Farber/Harvard Cancer Center, Boston, MA, USA

Lauren C. Harshman, MD. Assistant Professor of Medicine, Dana-Farber/Harvard Cancer Center, Boston, MA, USA
Specialties: Nephrology, Oncology, Urology
Topics: Carcinoma , Renal Cell Carcinoma